Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Year Invested: 2013
Location: Cambridge, Mass.

Recent News

May 3, 2018
Editas Medicine Announces First Quarter 2018 Results and Update

April 26, 2018
Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results

March 28, 2018
Editas Medicine Names James C. Mullen as Chairman of the Board of Directors

Read More News

Associated Team Members

Alexis Borisy